Reimagining Druggability

We are reimagining druggability using chemoproteomic platforms to develop transformative medicines.

Explore more

Our
Research

One of the greatest challenges that we face in discovering new disease therapies is that most proteins are considered “undruggable.” Our research group is reimagining druggability by using chemoproteomic approaches to tackle the undruggable proteome.

Meet Our Team

We are a group of highly motivated scientists with a desire to engage in multidisciplinary research at the interface of chemistry and biology.

Latest News

VIEW ALL NEWS
— NEWS

Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease

Financing led by a16z and Deerfield Management with participation from Droia Ventures, GV, The Mark Foundation for Cancer Research and the Berkeley Catalyst Fund Exclusive…
— NEWS

Novartis and UC Berkeley Extend Alliance to Tackle “Undruggable” Disease Targets and Discover New Therapeutic Modalities

July 28th, 2022 Novartis-Berkeley Translational Chemical Biology Institute combines Novartis expertise in chemical biology and medicinal chemistry with Berkeley’s expertise in covalent chemoproteomics and chemistry methodologiesResearch…
— NEWS

We’ve received the NCI R35 Outstanding Investigator Award!!

The NCI Outstanding Investigator Award (OIA) supports investigators with outstanding records of productivity in cancer research by providing extended funding stability and encouraging investigators to…
— NEWS

Congrats to Nate Henning and Lydia Boike for graduating with their PhD’s in Chemical Biology!

Nate Henning and Lydia Boike in our lab graduated with their Ph.D. in Chemical Biology from UC Berkeley! Congrats!!
— NEWS

Our paper on DUBTACs for targeted protein stabilization is now out!!

Congrats to co-first authors Nate Henning and Lydia Boike! https://www.nature.com/articles/s41589-022-00971-2.pdf

Help us advance
our research